Pro and contra duration restriction of treatment with willow bark extract

Phytotherapy Research

Volumn 28, Issue 1, 2014, Pages 148-149

  Vlachojannis, C ^a   Magora, F ^b   Chrubasik Hausmann, Sigrun ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

adverse events; NSAIDs; toxicity; treatment duration; willow bark

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT EXTRACT; SALICIN; UNCLASSIFIED DRUG; WILLOW BARK EXTRACT;

ANAPHYLAXIS; BACKACHE; BARK; BLOOD CLOTTING DISORDER; CHRONIC PAIN; DRUG CONTRAINDICATION; DRUG CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG UNDERDOSE; FEVER; FIBROMYALGIA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH CARE COST; HEMOLYSIS; HIGH RISK POPULATION; HUMAN; LETTER; MEDICAL HISTORY; MEDICAL LITERATURE; MUSCULOSKELETAL PAIN; NONHUMAN; OSTEOARTHRITIS; RISK BENEFIT ANALYSIS; STOMACH LESION; STOMACH MUCOSA LESION; TOXICITY TESTING; TREATMENT DURATION; TREATMENT DURATION RESTRICTION; WILLOW;

SALIX;

ADVERSE EVENTS; NSAIDS; TOXICITY; TREATMENT DURATION; WILLOW BARK;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; PHYTOTHERAPY; PLANT BARK; PLANT EXTRACTS; SALIX;

EID: 84892444877     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5008     Document Type: Letter

References (24)

1. Baker S, Thomas PS,. 1987. Herbal medicine precipitating massive haemolysis. Lancet 1 (8540): 1039-40.
2. Boullata JI, McDonnell PJ, Oliva CD,. 2003. Anaphylactic reaction to a dietary supplement containing willow bark. Ann Pharmacother 37: 832-5.
3. Chevat C, Peña BM, Al MJ, Rutten FF,. 2001. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics 19 Suppl 1: 17-32.
4. Chrubasik S, Künzel O, Thanner J, Conradt C, Black A,. 2005. A 1-year follow-up after a pilot study with Doloteffin for low back pain. Phytomedicine 12: 1-9.
5. Chrubasik S, Chrubasik C, Künzel O, Black A,. 2007. Patient-perceived benefit during one year of treatment with Doloteffin. Phytomedicine 14: 371-6.
6. Chrubasik C, Wiesner L, Black A, Müller-Ladner U, Chrubasik S,. 2008. A one-year survey on the use of a powder from Rosa canina lito in acute exacerbations of chronic pain. Phytother Res 22: 1141-8.
7. EMA. 2009. www.ema.europa.eu/docs/en-GB/document-library/Herbal-HMPC- assessment-report/2009/12/WC500018258.pdf
8. EMA Website. 2013; www.ema.europa.eu/ema/index.jsp?curl=search.jsp&q= Herbal+monographs&btnG=Search&mid=WC0b01ac05800240cf
9. Glinko A., 1998. Pharmacological properties of a standardized extract from Willow Bark (Cortex salicis). Chair of Pharmacology and Toxicology. Pomeranian Academy of Medicine, Szczecin.
10. Hunsche E, Chancellor JV, Bruce N,. 2001. The burden of arthritis and nonsteroidal anti-inflammatory treatment. A European literature review. Pharmacoeconomics 19: 1-15.
11. Krivoy N, Pavlotzky E, Chrubasik S, Eisenberg E, Brooks G,. 2001. Effect of Salicis Cortex extract on human platelet aggregation. Planta Med 67: 209-213.
12. MacDonald TM,. 2000. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology (Oxford)) 39: 13-20.
13. Müller-Faßbender H,., Müller J, Bach G,. 2007. Wirksamkeit und Verträglichkeit eines Weidenrindenpräparates bei Erkrankungen des Bewegungsapparates. Arthritis und Rheuma 27: 267-71.
14. O'Neil CK, Hanlon JT, Marcum ZA,. 2012. Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother 10: 331-42.
15. Pobłocka-Olech L, Krauze-Baranowska M,. 2008. SPE-HPTLC of procyanidins from the barks of different species and clones of Salix. J Pharm Biomed Anal 48: 965-8.
16. Pobłocka-Olech L, Krauze-Baranowska M, Głód D, Kawiak A, Łojkowska E,. 2010. Chromatographic analysis of simple phenols in some species from the genus Salix. Phytochem Anal 21: 463-9.
17. Reginster JY, Malmstrom K, Mehta A, et al. 2007. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 66: 945-51.
18. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C,. 2007. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 27: 1237-47.
19. Stone E,. 1763. An account of the success of the bark of the willow in the cure of agues. Philos Trans R Soc Lond 53: 195-200.
20. Uehleke B, Preis S, Mueller J, Stange R, Kelber O, Melzer J,. 2013. Willow bark extract STW 33-1 is safe and effective in the long-term treatment of outpatients with rheumatic pain, esp. osteoarthritis or back pain. A subgroup analysis. Zschr Phytother 34:S 24 (P 09).
21. Vlachojannis JE, Cameron M, Chrubasik S,. 2009. A systematic review on the effectiveness of willow bark for musculoskeletal pain. Phytother Res 23: 897-900.
22. Vlachojannis J, Magora F, Chrubasik S,. 2011. Willow Species and Aspirin: Different Mechanism of Actions. Phytother Res 25: 1102-4.
23. R) for chronic back pain and arthralgia, a post-authorization surveillance study. Congress Phytopharmaka and Phytotherapy, Feb. 26-28, Berlin.
24. Zenner-Weber MA,. 2004. Successful treatment of chronic rheumatic diseases (ICD M-codes) with willow bark extract (Assalix), a seeding trial. Gemeinsamer Kongress der Schweizer Gesellschaften für Rheumatologie und für Physikalische Medizin, Sept 16-17, Locarno.